Camidanlumab tesirine
Camidanlumab tesirine[edit]
Camidanlumab tesirine is a monoclonal antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It combines a monoclonal antibody targeting the protein CD25 with a cytotoxic agent, tesirine, to deliver targeted therapy to cancer cells.
Mechanism of Action[edit]
Camidanlumab tesirine works by targeting the CD25 protein, which is expressed on the surface of certain cancer cells, including some types of lymphoma and leukemia. The monoclonal antibody component of the drug binds to CD25, allowing the conjugated tesirine to be internalized by the cancer cell. Once inside, tesirine is released and induces cell death by damaging the DNA of the cancer cell.
Development and Clinical Trials[edit]
Camidanlumab tesirine is currently under investigation in clinical trials for its efficacy and safety in treating various cancers. It has shown promise in early-phase trials, particularly in patients with relapsed or refractory Hodgkin lymphoma.
Side Effects[edit]
As with many cancer therapies, camidanlumab tesirine can cause a range of side effects. Common side effects include fatigue, nausea, and hematological toxicities such as neutropenia and thrombocytopenia. More serious side effects may include liver toxicity and infusion-related reactions.
